• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 14, 2014

View Archived Issues

Victory at last in DMD: Santhera phase III hits FDA-blessed lung function endpoint

Having scored landmark phase III success against Duchenne muscular dystrophy (DMD) with idebenone, an oral drug that does not depend on patients' mutational status, Santhera Pharmaceuticals AG is heading to the FDA to talk about next steps. Read More

In hot pursuit: Pfizer hints it may raise bid; CEOs grilled in UK

LONDON - Pfizer Inc. has increased the pressure on Astrazeneca plc, publishing a presentation to the UK company's shareholders in which it outlines the strategic rationale for the proposed £63 billion (US$107 billion) takeover, and hints it is prepared to increase the offer. Read More

Marinus Pharma files for IPO to fuel epilepsy program

Despite the prevailing uncertain financial markets, the lure of going public has not diminished for biotech companies, with New Haven, Conn.-based Marinus Pharmaceuticals Inc. joining a list of 18 other companies currently lining up on the initial public offering (IPO) runway. Read More

Mabvax going public through Telik merger

Mabvax Therapeutics Inc., a privately held cancer immunotherapy company, is taking the fast lane to Nasdaq through a merger with publicly traded Telik Inc., which will fade out in the deal's wake. Read More

Gene Signal sees enough in aganirsen phase III data for follow-up trial

Aganirsen, a topical antisense drug in development for treating inflammation-related corneal neovascularization (CNV), failed to reach the primary endpoint of visual acuity in a phase III trial, but its developer Gene Signal International SA plans to start a confirmatory trial later this year based on a different endpoint, having seen a significant reduction in the extent of neovascularization between the two treatment groups. Read More

Go early, go big, go global: Aslan licenses preclinical MAb for asthma

SHANGHAI – Aslan Pharmaceuticals Pte Ltd. signed an agreement for global rights with CSL Ltd. to develop an anti-IL-13 receptor monoclonal antibody, CSL334, for severe to moderate asthma. Read More

Further doubts cast on purported STAP stem cell technique

HONG KONG – Chinese University of Hong Kong (CUHK) researchers reported being unable to replicate controversial research purporting to create stimulus-triggered acquisition of pluripotent (STAP) stem cells, which behave like induced pluripotent stem (iPS) cells, by simple acid-based treatment of somatic cells, suggesting that the method is not as simple or as straightforward as initially claimed. Read More

FDA issues biosimilar guidance, mute on interchangeability

The FDA released the latest installment in its series of draft biosimilar guidances Tuesday, but it's not the one many drugmakers are anxiously awaiting. The newest guidance discusses the design and use of clinical pharmacology studies. Pharmacokinetic (PK) and pharmacodynamic (PD) data are required as part of the FDA's stepwise approach to demonstrating biosimilarity to the reference drug. Read More

Other news to note

Jubilant Biosys Ltd., of Bangalore, India, and Orion Corp., of Espoo, Finland, disclosed a drug discovery collaboration to discover small-molecule inhibitors in the neuroscience therapeutic area. Read More

Stock movers

Read More

Clinic roundup

Basilea Pharmaceutica Ltd., of Basel, Switzerland, reported that a phase III trial showed its antibiotic ceftobiprole to demonstrate more rapid clinical responses in hospital-acquired pneumonia and community-acquired pneumonia than a comparator regimen. Read More

Pharma: Other news to note

Janssen Pharmaceuticals Inc., of Titusville, N.J., a unit of Johnson & Johnson, said it submitted a supplemental new drug application for once-monthly atypical long-acting antipsychotic Invega Sustenna (paliperidone palmitate) to the FDA for approval to treat schizoaffective disorder as either monotherapy or adjunctive therapy. Read More

Earnings roundup

Arena Pharmaceuticals Inc., of San Diego, reported that for the first quarter ending March 31, approximately 77,000 prescriptions for Belviq (lorcaserin HCl) were filled, according to IMS Health, representing growth of approximately 31 percent in total prescriptions as compared to the previous quarter. Read More

Pharma: Clinic roundup

Astrazeneca plc, of London, reported phase III data showing that the combination of saxagliptin/dapagliflozin, as a dual add-on therapy in adults with type 2 diabetes who were inadequately controlled on metformin, resulted in statistically significant reductions in HbA1c with the combination vs. either agent alone. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe